BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
Public ClinicalTrials.gov record NCT00749190. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (1 mg, 5 mg, 10 mg, 25 mg, and 50 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo With an Additional Open-label Sitagliptin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control Despite Metformin Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM with insufficient glycemic control. In addition, there will be an open-label treatment arm with sitagliptin (JanuviaTM) as add-on therapy to metformin.
Study identification
- NCT ID
- NCT00749190
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 495 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2008 (Type not available)
- Primary completion
- Oct 2009 (Actual)
- Completion
- Not listed
- Last update posted
- Jun 13, 2014
Started 2008
United States locations
- U.S. sites
- 19
- U.S. states
- 10
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1245.10.10026 Boehringer Ingelheim Investigational Site | Chula Vista | California | — | — |
| 1245.10.10001 Boehringer Ingelheim Investigational Site | Mission Viejo | California | — | — |
| 1245.10.10011 Boehringer Ingelheim Investigational Site | Pasadena | California | — | — |
| 1245.10.10028 Boehringer Ingelheim Investigational Site | Spring Valley | California | — | — |
| 1245.10.10027 Boehringer Ingelheim Investigational Site | Walnut Creek | California | — | — |
| 1245.10.10004 Boehringer Ingelheim Investigational Site | Clearwarter | Florida | — | — |
| 1245.10.10021 Boehringer Ingelheim Investigational Site | Melbourne | Florida | — | — |
| 1245.10.10005 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1245.10.10019 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1245.10.10024 Boehringer Ingelheim Investigational Site | Saint Cloud | Florida | — | — |
| 1245.10.10014 Boehringer Ingelheim Investigational Site | Roswell | Georgia | — | — |
| 1245.10.10016 Boehringer Ingelheim Investigational Site | Staten Island | New York | — | — |
| 1245.10.10009 Boehringer Ingelheim Investigational Site | Shelby | North Carolina | — | — |
| 1245.10.10006 Boehringer Ingelheim Investigational Site | Wadsworth | Ohio | — | — |
| 1245.10.10023 Boehringer Ingelheim Investigational Site | Norristown | Pennsylvania | — | — |
| 1245.10.10010 Boehringer Ingelheim Investigational Site | Clemson | South Carolina | — | — |
| 1245.10.10015 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1245.10.10012 Boehringer Ingelheim Investigational Site | Temple | Texas | — | — |
| 1245.10.10025 Boehringer Ingelheim Investigational Site | Federal Way | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 97 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00749190, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 13, 2014 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00749190 live on ClinicalTrials.gov.